Inventor · disambiguated record
Samuel Weisbrod
Also filed as: WEISBROD SAMUEL
6 granted patents·15 pending applications·7 citations·filing 2012–2025
71Inventor score
Files withASCENDIS PHARMA AS13ASCENDIS PHARMA ONCOLOGY DIV A/S5ASCENDIS PHARMA OPHTHALMOLOGY DIV A/S2ASCENDIS PHARMA GROWTH DISORDERS DIV AS1
Top patents by PatentIndex Score
21 records- 0179US11642415B2Hydrogel cross-linked hyaluronic acid prodrug compositions and methodsASCENDIS PHARMA AS·Filed 2019·Granted May 9, 2023·1 cites·28 claims
- 0274US12246070B2Hydrogel cross-linked hyaluronic acid prodrug compositions and methodsASCENDIS PHARMA AS·Filed 2023·Granted Mar 11, 2025·0 cites·4 claims
- 0373US10519226B2VEGF neutralizing prodrugs for the treatment of ocular conditionsASCENDIS PHARMA OPHTHALMOLOGY DIV A/S·Filed 2013·Granted Dec 31, 2019·6 cites·21 claims
- 0466US2023116809A1Prevention and treatment of ocular conditionsASCENDIS PHARMA OPHTHALMOLOGY DIV A/S·Filed 2022·Application pending·0 cites
- 0563US2025255973A1Hydrogel cross-linked hyaluronic acid prodrug compositions and methodsASCENDIS PHARMA AS·Filed 2025·Application pending·0 cites
- 0661US10040850B2Protecting group comprising a purification tagASCENDIS PHARMA AS·Filed 2014·Granted Aug 7, 2018·0 cites·14 claims
- 0756US2024075150A1Conjugates comprising reversible linkers and uses thereofASCENDIS PHARMA AS·Filed 2023·Application pending·0 cites
- 0851US2015010634A1Prevention and treatment of ocular conditionsASCENDIS PHARMA AS·Filed 2012·Application pending·0 cites
- 0950US2018312582A1Protecting Group Comprising a Purification TagASCENDIS PHARMA AS·Filed 2018·Application pending·0 cites
- 1049US2023110994A1Conjugates undergoing intramolecular rearrangementsASCENDIS PHARMA AS·Filed 2020·Application pending·0 cites
- 1147US2023065814A1Conjugates of-electron-pair-donating heteroaromatic nitrogen-comprising compoundsASCENDIS PHARMA AS·Filed 2020·Application pending·0 cites
- 1247US2022304993A1Conjugates of an electron-donating nitrogen or tertiary amine comprising compoundsASCENDIS PHARMA AS·Filed 2020·Application pending·0 cites
- 1347US2017112939A1Prevention and treatment of ocular conditionsASCENDIS PHARMA GROWTH DISORDERS DIV AS·Filed 2017·Application pending·0 cites
- 1447US2022305129A1Conjugates of heteroaromatic nitrogen-comprising compoundsASCENDIS PHARMA AS·Filed 2020·Application pending·0 cites
- 1545US2022054476A1Sustained local drug levels for innate immune agonistsASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 1645US2022054478A1Minimization of systemic inflammationASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 1745US2022054477A1Induction of sustained local inflammationASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 1845US2023102309A1Tyrosine kinase inhibitor conjugatesASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 1942US11896671B2Conjugation method for carrier-linked prodrugsASCENDIS PHARMA AS·Filed 2017·Granted Feb 13, 2024·0 cites·24 claims
- 2042US2022062273A1Conjugates of pattern recognition receptor agonistsASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 2141US11298427B2Prodrugs comprising a pyroglutamate linkerASCENDIS PHARMA AS·Filed 2016·Granted Apr 12, 2022·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when Samuel Weisbrod files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →